215 related articles for article (PubMed ID: 19956806)
21. [Pazopanib (Votrient) in the management of renal cell cancer and soft tissue sarcomas].
Gennigens C; Jerusalem G
Rev Med Liege; 2012; 67(7-8):437-42. PubMed ID: 22984765
[TBL] [Abstract][Full Text] [Related]
22. Good tolerability, long-term survival and easy management of side effects in a patient with metastatic renal cell carcinoma treated with pazopanib.
Frascaroli M; Di Cesare P
Tumori; 2014; 100(6):e301-4. PubMed ID: 25688516
[TBL] [Abstract][Full Text] [Related]
23. [Tyrosine kinase inhibitor as adjuvant treatment of renal cell carcinoma: 1 versus 3].
Penel N
Bull Cancer; 2017 Sep; 104(9):705-706. PubMed ID: 28760312
[No Abstract] [Full Text] [Related]
24. Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea.
Jo J; Kim JH; Kim JY; Hyun C; Rhee J; Kwon J; Han S; Kim W
Cancer Res Treat; 2016 Jan; 48(1):393-7. PubMed ID: 25715772
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of pazopanib administered in combination with bevacizumab.
Imbs DC; Négrier S; Cassier P; Hollebecque A; Varga A; Blanc E; Lafont T; Escudier B; Soria JC; Pérol D; Chatelut E
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1189-96. PubMed ID: 24705975
[TBL] [Abstract][Full Text] [Related]
26. Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
Leung HW; Chan AL
Clin Ther; 2011 Jun; 33(6):708-16. PubMed ID: 21704235
[TBL] [Abstract][Full Text] [Related]
27. Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone.
Vrdoljak E; Rini B; Schmidinger M; Omrčen T; Torday L; Szczylik C; Sella A
Anticancer Drugs; 2013 Jun; 24(5):431-40. PubMed ID: 23511427
[TBL] [Abstract][Full Text] [Related]
28. Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
Bellmunt J; Pons F; Foreshew A; Fay AP; Powles T; Porta C; Bracarda S; Lampron ME; Cerbone L; Sternberg CN; Hutson TE; Choueiri TK
Clin Genitourin Cancer; 2014 Aug; 12(4):262-9. PubMed ID: 24795159
[TBL] [Abstract][Full Text] [Related]
29. Nursing considerations with pazopanib therapy: focus on metastatic renal cell carcinoma.
Bourdeanu L; Twardowski P; Pal SK
Clin J Oncol Nurs; 2011 Oct; 15(5):513-7. PubMed ID: 21951737
[TBL] [Abstract][Full Text] [Related]
30. SU11248 and AG013736: current data and future trials in renal cell carcinoma.
Rini BI
Clin Genitourin Cancer; 2005 Dec; 4(3):175-80. PubMed ID: 16425985
[TBL] [Abstract][Full Text] [Related]
31. [First-line therapy of advanced or metastasized renal cell cancer: open randomized phase III sequence study to examine the effectiveness and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of patients with advanced or metastasized renal cell cancer (SWITCH-2 - AN 33/11)].
Rexer H
Urologe A; 2012 May; 51(5):724-6. PubMed ID: 22576149
[No Abstract] [Full Text] [Related]
32. Cardiac metastasis from renal cell carcinoma successfully treated with pazopanib: impact of TKIs' antiangiogenic activity.
Schinzari G; Monterisi S; Signorelli D; Cona MS; Cassano A; Danza F; Barone C
Tumori; 2014; 100(6):e298-300. PubMed ID: 25688515
[TBL] [Abstract][Full Text] [Related]
33. Targeted therapy in renal carcinoma: a case of long-term effect with complete control of toxicity.
Conforti S; Ceniti S; Conforti L; Turano S; Minardi S; Palazzo S
Tumori; 2014; 100(6):e293-7. PubMed ID: 25688514
[TBL] [Abstract][Full Text] [Related]
34. Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.
Hainsworth JD; Rubin MS; Arrowsmith ER; Khatcheressian J; Crane EJ; Franco LA
Clin Genitourin Cancer; 2013 Sep; 11(3):270-5. PubMed ID: 23665131
[TBL] [Abstract][Full Text] [Related]
35. Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
Santoni M; Conti A; Porta C; Procopio G; Sternberg CN; Basso U; De Giorgi U; Bracarda S; Rizzo M; Ortega C; Massari F; Iacovelli R; Derosa L; Masini C; Milella M; Di Lorenzo G; Atzori F; Pagano M; Buti S; De Vivo R; Mosca A; Rossi M; Paglino C; Verzoni E; Cerbone L; Muzzonigro G; Falconi M; Montironi R; Burattini L; Santini D; Cascinu S
J Urol; 2015 Jan; 193(1):41-7. PubMed ID: 25046616
[TBL] [Abstract][Full Text] [Related]
36. Pazopanib: Clinical development of a potent anti-angiogenic drug.
Schutz FA; Choueiri TK; Sternberg CN
Crit Rev Oncol Hematol; 2011 Mar; 77(3):163-71. PubMed ID: 20456972
[TBL] [Abstract][Full Text] [Related]
37. Pazopanib: a Review in Advanced Renal Cell Carcinoma.
Frampton JE
Target Oncol; 2017 Aug; 12(4):543-554. PubMed ID: 28664385
[TBL] [Abstract][Full Text] [Related]
38. Preclinical impact of high dose intermittent antiangiogenic tyrosine kinase inhibitor pazopanib in intrinsically resistant tumor models.
Reguera-Nuñez E; Man S; Xu P; Kerbel RS
Angiogenesis; 2018 Nov; 21(4):793-804. PubMed ID: 29786782
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma.
Hutson TE; Davis ID; Machiels JP; De Souza PL; Rottey S; Hong BF; Epstein RJ; Baker KL; McCann L; Crofts T; Pandite L; Figlin RA
J Clin Oncol; 2010 Jan; 28(3):475-80. PubMed ID: 20008644
[TBL] [Abstract][Full Text] [Related]
40. Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial.
Bracarda S; Bellmunt J; Melichar B; Négrier S; Bajetta E; Ravaud A; Sneller V; Escudier B
BJU Int; 2011 Jan; 107(2):214-9. PubMed ID: 20942831
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
